# Phase IIa Clinical Trial of YN001 in Patients With Atherosclerotic Cardiovascular and Cerebrovascular Diseases and Erectile Dysfunction

> **NCT07311330** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Beijing Inno Medicine Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Atherosclerotic Cardiovascular Disease (ASCVD)
- Erectile Dysfunction

## Interventions

- **DRUG:** YN001 20mg Dose + 5% glucose injection
- **OTHER:** 5% glucose injection

## Key facts

- **NCT ID:** NCT07311330
- **Lead sponsor:** Beijing Inno Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-31
- **Primary completion:** 2026-06-16
- **Final completion:** 2026-11-14
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07311330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07311330, "Phase IIa Clinical Trial of YN001 in Patients With Atherosclerotic Cardiovascular and Cerebrovascular Diseases and Erectile Dysfunction". Retrieved via AI Analytics 2026-07-23 from https://api.ai-analytics.org/clinical/NCT07311330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*